Exchange: NASDAQ·Updated 12:49 PM EDT
News
all
press releases
Janux Therapeutics, Inc. (JANX) Reports Q2 Loss, Lags Revenue Estimates
Janux Therapeutics (JANX) delivered earnings and revenue surprises of -34.62% and -72.33%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
More News
EyePoint (EYPT) Reports Q2 Loss, Beats Revenue Estimates
EyePoint (EYPT) delivered earnings and revenue surprises of -18.48% and +102.80%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
CRVO Stock Rockets Nearly 100% On Patent Win Before Offering News Cools Rally
The new patent for neflamapimod covers the treatment of dementia with Lewy bodies in patients without significant signs of Alzheimer’s disease.
Stocktwits
Emerging Growth Stocks Enter Breakout Territory
A wave of high-impact developments is drawing investor attention as multiple emerging growth companies advance toward potentially transformative milestones. $CRVO, $NTHI, $CAST, $LNKS, $BFLY, $QS, $APWC
24-7 Market News
Brains, AI Imaging, and Breakthrough Antibiotics Ignite Investor Buzz
The healthcare and biotechnology sector continues to generate a steady stream of meaningful catalysts as companies advance novel therapies, secure regulatory milestones, strengthen intellectual property portfolios, and expand commercialization efforts. Recent developments from CervoMed (NASDAQ:CRVO), Butterfly Network (NYSE:BFLY), NeOnc (NASDAQ:NTHI), Spero Therapeutics (NASDAQ:SPRO), GSK (NYSE:GSK), and IceCure Medical (NASDAQ:ICCM) highlight several emerging themes shaping the sector, including neurodegenerative disease treatment, AI-powered diagnostics, antimicrobial resistance, minimally invasive cancer care, and synthetic biology.
24-7 Market News
Power Hour Breakouts: Clinical Catalysts and New Highs Send Traders Hunting for the Next Winner
Clinical milestones, regulatory progress, insider buying, and newly public biotechnology platforms are among the leading themes for today’s power hour. $CRVO, $NTHI, $SLBT, $SPCX, $WULF, $AMAT, $EW, $OSCR
24-7 Market News
Biotech Bulls Stampede as Clinical Wins and Milestones Fuel Momentum
Multiple clinical-stage companies are delivered meaningful regulatory, clinical, and corporate milestones. From brain cancer drug development and cell therapy expansion to neurodegenerative disease programs and cardiovascular breakthroughs, investors were presented with a wave of catalysts that are driving enthusiasm across several emerging healthcare names. Traders appeared particularly focused on companies advancing toward late-stage clinical development, securing new regulatory clearances, or gaining broader visibility through public market events. $NTHI, $SLBT, $CRVO, $EWTX
24-7 Market News
Why Did CRVO Stock Crash 22% In Pre-Market Trading Today?
CervoMed announced a $10.5 million private placement financing, with participation from institutional healthcare investors and company insiders.
Stocktwits
Pelthos Therapeutics Inc. (PTHS) Reports Q1 Loss, Beats Revenue Estimates
Pelthos Therapeutics Inc. (PTHS) delivered earnings and revenue surprises of +22.75% and +12.03%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Caribou Biosciences, Inc. (CRBU) Reports Q1 Loss, Misses Revenue Estimates
Caribou Biosciences (CRBU) delivered earnings and revenue surprises of +21.81% and -4.12%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks

Advertisement|Remove ads.